NWRD06 DNA Plasmid for HCC After Curative Resection.

Summary

This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after curative resection.

Timeline

Start

2025-12-08

Primary completion

2028-12-31

Completion

2028-12-31

Drugs

Indications